A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma
Compared to ccRCC, the plasma proteome of metastatic ChRCC is dominated by mitochondrial metabolic enzymes, revealing a systemic metabolic phenotype strikingly aligned with the known histologic accumulation of abnormal mitochondria in ChRCC cells.
Authors
- Liliana Ascione (ORCID: https://orcid.org/0000-0002-2807-7400)
- Yehonatan Elon
- Steven Safi (ORCID: https://orcid.org/0000-0002-7634-8439)
- Wafaa Bzeih (ORCID: https://orcid.org/0000-0002-3643-7509)
- Vinay K. Giri (ORCID: https://orcid.org/0000-0003-4612-1003)
- Tiegang Han
- Adam P. Dicker (ORCID: https://orcid.org/0000-0003-0733-3337)
- Jessica F. Williams (ORCID: https://orcid.org/0000-0001-6696-7909)
- Clara Steiner (ORCID: https://orcid.org/0009-0008-8640-1636)
- Yi Tang (ORCID: https://orcid.org/0000-0003-1597-0141)
- Hadi Mansour
- Eddy Saad
- Elizabeth P. Henske
- Toni K. Choueiri
- Wenxin Xu
- Michelle S. Hirsch
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Milan (IT)
- University of Utah (US)
- Henry Ford Hospital (US)
- Sidney Kimmel Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- University Hospital Leipzig (DE)
- Israel Cancer Association (IL)
- European Institute of Oncology (IT)
Publication Details
- Journal
- Cancers
- Published
- 2026-03-23
- DOI
- https://doi.org/10.3390/cancers18061032
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00